Stoke Therapeutics assumed with a Buy at Canaccord

Canaccord analyst Sumant Kulkarni assumed coverage of Stoke Therapeutics with a Buy rating and $24 price target. Stoke’s proprietary TANGO platform is "conceptually/scientifically elegant" and can generate pipeline candidates that can be first-in-class and disease-modifying, the analyst argues. Lead candidate STK-001 is in Phase 1/2a trials for Dravet syndrome and the firm views interim data as "encouraging," the analyst tells investors.